

30 April 2024

Appointment of Tim Tian as Group CFO

Melodiol Global Health Limited (ASX:ME1) ('Melodiol' or 'the Company') is pleased to advise that it has appointed Mr Yuan (Tim) Tian as group CFO, effective 1 May 2024. As part of the executive team, Mr Tian will oversee the Company's financial planning and analysis, accounting and controllership, taxation, and audit and compliance. Mr Tian has been with the Company for over three years and currently serves as the group's Financial Controller. Mr Tian holds the following designations: Master of Professional Accounting, Master of Finance and is currently completing an MBA. Mr Tian is a Member of the CPA of Australia and the CA of ANZ and has more than 15 years of experience in financial controllership roles. Mr Tian has demonstrated excellence throughout his tenure with the Company and has held a highly significant role within the group's finance function. As such, management and the board are confident that Mr Tian will transition seamlessly and successfully into his new role.

The Company would like to thank current CFO, Mr Chris Grundy for all of his efforts and contributions since his appointment as Group CFO in 2017. Mr Grundy has been an integral part of the leadership team over the past seven years and the Company wishes him well in his retirement.

Management commentary:

CEO and Managing Director, Mr William Lay said: *"I would like to take this opportunity to welcome Tim to the executive team. I have worked with Tim for several years and he has been a tremendous asset to the Company. The board and I are excited about his new role and confident that he will be highly successful.*

I would also like to thank Chris for his incredible contributions to the Company over the preceding years. It has been a pleasure working with him and the Company wishes him all the best."

-Ends-

Authority and Contact Details

This announcement has been authorised for release by the Disclosure Committee of Melodiol Global Health Limited.

For further information, please contact:

Investor Enquiries

Melodiol Global Health Limited

E: info@cresopharma.com

P: +61 (0) 497 571 532

About Melodiol

Melodiol Global Health Limited (ASX:ME1) brings the best of cannabis and other plant-based products to better the lives of people and animals. Melodiol strives for the highest quality in its products. It develops cannabis, hemp-derived and other plant based therapeutic, nutraceutical, and lifestyle products with wide consumer reach.

To learn more please visit: <https://melodiolglobalhealth.com/>

Melodiol offices:

Australia: Suite 5 CPC, 145 Stirling Hwy, Nedlands, WA, 6009

Canada: 59 Payzant Drive, Windsor, Nova Scotia, B0N 2T0 and 50 Ivey Ln, Windsor, Nova Scotia, B0N 2T0

Forward Looking statements

This announcement contains forward-looking statements with respect to Melodiol and its respective operations, strategy, investments, financial performance and condition.

These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Melodiol could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Melodiol and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Melodiol has no obligation to up-date such statements, except to the extent required by applicable laws.